TScan Therapeutics, Inc. (NASDAQ:TCRX)
| Market Cap | $9.27M-85.3% |
| Revenue (ttm) | $5.19M-38.4% |
| Net Income | -$115.09M+19.3% |
| EPS | -$0.88+21.4% |
| Shares Out | 63.50M |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 391,711 |
| Open | $0.14 |
| Previous Close | $0.14 |
| Day's Range | $0.14 - $0.15 |
| 52-Week Range | $0.14 - $1.47 |
| Beta | 1.19 |
| Analysts | Buy |
| Price Target | $1.00(+585.40%) |
| Earnings Date | Mar 3, 2027 |
About TCRX
TScan Therapeutics, Inc., a clinical-stage biotechnology company, develops T cell receptor-engineered T cell (TCR-T) therapies for the treatment of patients with cancer in the United States. The company’s lead product is TSC-101, for the treatment of patients with acute myeloid leukemia (AML), myelodysplastic syndrome (MDS), and acute lymphoblastic leukemia (ALL) in patients undergoing allogeneic hematopoietic cell transplantation (HCT), which is in Phase I clinical trial, as well as eliminates residual disease and promotes donor chimerism. It also develops TSC-102-A01 and TSC-102-A03, which are allogeneic and donor-derived TCR-T therapy candidates targeting epitopes. In addition, the company develops TSC-200, TSC-201, TSC-202, TSC-203, and TSC-204 for the treatment of solid tumors. It has a research collaboration and license agreement with Amgen Inc. to identify antigens recognized by T cells in patients with Crohn’s disease. TScan Therapeutics, Inc. was incorporated in 2018 and is headquartered in Waltham, Massachusetts.
What Are Insiders Doing?
View the trades behind this meter — each links to its SEC Form 4 →
Open-market Form 4 purchases (code P) vs sales (code S) on file for this company. Grants, option exercises and tax withholdings are excluded. Informational only.
Analyst consensus
3 firms rating TCRX in the last 3 months, one vote each. Issuer-paid research is not counted.
Next catalysts
- Mar 3, 2027Earnings report
$TCRX stock is featured in our Insider Trades datasets.
→ All Stock ListsRecently reported changes in TCRX holdings by institutional investors
Latest 0 13F filings · Source: SEC EDGAR
View all institutional owners →Insider Trading
Quarterly net insider trading by TCRX's directors and management
Source: SEC EDGAR (Form 4)
Corporate Lobbying
TCRX Estimated quarterly lobbying spending
Source: U.S. Senate LDA
TCRX Revenue by Segment
| Laboratory supplies, research materials and studies | $6.00M | 36.32% |
| Clinical studies | $4.61M | 27.89% |
| Legal and professional fees | $1.95M | 11.78% |
| Facility-related and other | $1.58M | 9.58% |
| Stock-based compensation | $1.08M | 6.52% |
| Interest and other income, net | $721.00K | 4.36% |
| Collaboration and license revenue | $586.00K | 3.55% |
As of: Q3 2026 (Sep 30, 2026) · Source: SEC EDGAR (10-Q)
U.S. Patents
New TCRX patent grants
Source: USPTO Open Data Portal
Government Contracts
Estimated quarterly amount awarded to TCRX from public contracts
Source: USAspending.gov
Top ETF Holders
ETFs with the largest estimated holdings in TCRX
| VTIVanguard Morningstar Total Stock Market ETF | $253.45K |
| VXFVanguard Extended Market ETF | $116.17K |
| IWCiShares Micro-Cap ETF | $22.03K |
| BUSMEA Series Trust - EA Bridgeway Ultra-Small Company Market ETF | $10.00K |
Estimated from each fund’s disclosed top holdings × AUM
Bull Case vs Bear Case
AI-generated from TCRX’s recent data — informational, not investment advice
What’s Behind the Score
Recent Insider Activity
Frequently Asked Questions
ETFs that hold this stock
| BUSM | EA Series Trust - EA Bridgeway Ultra-Small Company Market ETF | 0.01% |
Weight is the stock’s share of each fund’s holdings.
